Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

FGFR2b inhibitor

DRUG CLASS:

FGFR2b inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

FGFR2b overexpression + HER-2 negative	Gastric Cancer	FGFR2b overexpression + HER-2 negative	Gastric Cancer	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B
FGFR2b overexpression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	FGFR2b overexpression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B
FGFR2 overexpression	Gastric Cancer	FGFR2 overexpression	Gastric Cancer	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2
FGFR2b overexpression	Gastroesophageal Junction Adenocarcinoma	FGFR2b overexpression	Gastroesophageal Junction Adenocarcinoma	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2
FGFR2b overexpression	Gastric Cancer	FGFR2b overexpression	Gastric Cancer	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2
FGFR2b expression	Gastroesophageal Junction Adenocarcinoma	FGFR2b expression	Gastroesophageal Junction Adenocarcinoma	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3
FGFR2b expression	Gastric Cancer	FGFR2b expression	Gastric Cancer	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3
FGFR2b positive	Gastroesophageal Junction Adenocarcinoma	FGFR2b positive	Gastroesophageal Junction Adenocarcinoma	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3
FGFR2b positive	Gastric Cancer	FGFR2b positive	Gastric Cancer	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3	AMG 552 Sensitive: C3 – Early Trials AMG 552 Sensitive : C3
FGFR2b expression	Gastric Cancer	FGFR2b expression	Gastric Cancer	GB2102 Sensitive: D – Preclinical GB2102 Sensitive : D	GB2102 Sensitive: D – Preclinical GB2102 Sensitive : D